Optimised Robust Treatment Plans for Prostate Cancer Focal Brachytherapy
暂无分享,去创建一个
Annette Haworth | John M. Betts | Christopher Mears | Hayley M. Reynolds | Martin A. Ebert | Guido Tack | John M. Betts | Kevin Leo | Kevin Leo | M. Ebert | Guido Tack | A. Haworth | H. Reynolds | C. Mears
[1] Jean Pouliot,et al. The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs. , 2004, International journal of radiation oncology, biology, physics.
[2] Seong Ki Mun,et al. Modeling and mapping of prostate cancer , 2000, Comput. Graph..
[3] J. Williamson,et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .
[4] Jacques Ferlay,et al. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .
[5] R. J. Gallagher,et al. Treatment planning for brachytherapy: an integer programming model, two computational approaches and experiments with permanent prostate implant planning. , 1999, Physics in medicine and biology.
[6] Annette Haworth,et al. Validation of a radiobiological model for low-dose-rate prostate boost focal therapy treatment planning. , 2013, Brachytherapy.
[7] Adam P Dicker,et al. Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group , 2012, BJU international.
[8] Mark Emberton,et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer , 2012, BJU international.
[9] R. Stock,et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. , 2001, International journal of radiation oncology, biology, physics.
[10] Martin Bues,et al. Effect of random seed placement error in permanent transperineal prostate seed implant. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] Wayne M Butler,et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. , 2012, Brachytherapy.
[12] Howard Pai,et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.
[13] Y. Yu,et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. , 2001, International journal of radiation oncology, biology, physics.
[14] Annette Haworth,et al. Assessment of i-125 prostate implants by tumor bioeffect. , 2004, International journal of radiation oncology, biology, physics.
[15] J Pouliot,et al. Monte Carlo simulations of prostate implants to improve dosimetry and compare planning methods. , 1999, Medical physics.
[16] Jeremy L Millar,et al. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[17] Nathan Lawrentschuk,et al. The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review , 2014, European urology.
[18] R. Stock,et al. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. , 2007, Urology.